single-arm trials · single-arm trials a good step towards faster access/reimbursement of drugs?...
TRANSCRIPT
![Page 1: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/1.jpg)
Single-arm trials
a good step towards faster
access/reimbursement of drugs?
(with an added value for ‘all’ patient…)
Mattias Neyt, MSc, PhD
Senior health economist
EMA, 30 June 2016
![Page 2: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/2.jpg)
Overview Are you aware of…
• Development success rate of drugs
• Prices vs. added value
• Impact on surrogate endpoints vs. survival & QoL
• Registration vs. reimbursement
• (Small?) impact on inefficient use of limited resources
• Importance of HTA
Some things to think about…
Open question: are single-arm trials (and other systems
to provide faster access) the best way to provide added
value to all patients?
2
![Page 3: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/3.jpg)
3
Source: www.biotech-now.org
LOA from phase I phase III
- Non-oncology: 12% 53%
- Oncology: 6.6% 37%
NDA: New Drug Application
BLA: Biological License Application
LOA: Letter of Authorization
Source: Light, Cancer, 2013
Phase III development success rate
Huge prices for cancer drugs
vs. modest gains
![Page 4: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/4.jpg)
Surrogate vs. survival (& QoL)
4
Request better evidence
before widespread use…
![Page 5: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/5.jpg)
5
Source: Kim, JAMA, 2015
![Page 6: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/6.jpg)
Propensity score Major concern: no good
estimate of treatment effect
misinformation
6 Source: Dahabreh, JAMA, 2014
![Page 7: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/7.jpg)
Safety
Quality
Efficacy
Cost-
effectiveness (Acceptability)
Budget impact (Affordability)
A 5th hurdle
The 4th
hurdle
Regulatory procedure – Registration HTA – Reimbursement
Registration vs. reimbursement Awareness,
early dialogues,
guidelines…
Comparative effectiveness
(comparator, endpoints, …)
3
![Page 8: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/8.jpg)
Small population ~ small BI?
8
Source: Van Hecke, Test Aankoop, 2016
Daily doses Expenditures
Personalized cancer drugs Conventional cancer drugs
Crucial: what is
their added value
vs. alternatives?!?
![Page 9: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/9.jpg)
Goal:
• Micro level (ST) Support decision makers by providing them objective, transparent, and scientifically based information.
• Macro level (LT, ‘all’ patients)
– Accessibility,
– High quality,
– Affordability / sustainability (LT!)
Why HTA?
9
!
![Page 10: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/10.jpg)
Something to think about…
Some concerns with SAT
• Reliable info on therapeutic added value?
• Causing recruitment problems in other studies?
• Faster access vs. faster/better reimbursement?
Without reliable evidence: possible harm &
waste of money (on societal level: try to do the
best for ALL patients)
• Can we do better? SAT should not be the
standard, only in exceptional well-considered
cases (e.g. >>> treatment effect)
10
![Page 11: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/11.jpg)
For your information
EUnetHTA guideline “Internal validity of non-
randomised studies (NRS) on interventions”
11
![Page 12: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/12.jpg)
Something to think about…
Steps in the good direction that need further
support
• International collaboration: better organisation of clinical
trials (ECRIN, IRCI, EORTC, …)
• Early dialogues: valuing cancer treatments with a focus
on both regulatory approval AND HTA/reimbursement
• More transparency of clinical trial results (theory vs.
practice)
• Pragmatic comparative effectiveness trials
• Use appropriate research design for appropriate
purposes (example: see next slide)
12
![Page 13: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/13.jpg)
13
• If we have some time… possible approach: Combine strengths of both
RCTs and observational data… Source: Neyt
et al., Health
Policy, 2012 !
![Page 14: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/14.jpg)
Open for discussion
What is your definition of ‘innovation’?
What is your goal (faster access vs. added value)?
Do you achieve this with single-arm trials?
HTA/reimbursement is national responsibility
… BUT major influence of European policy
• Lowering standards shifting the problem
• Is it wise to shift the burden of generating evidence
from pre-marketing to post-marketing?
14
![Page 15: Single-arm trials · Single-arm trials a good step towards faster access/reimbursement of drugs? (with an added value for ‘all’ patient…) Mattias Neyt, MSc, PhD](https://reader033.vdocuments.us/reader033/viewer/2022042115/5e9275ea0b428701661d3c47/html5/thumbnails/15.jpg)
15
THANK YOU!